The global cervical cancer market for drugs and diagnostics was $11.3 billion in 2012 and is expected to grow from $11.6 billion in 2013 to $15.6 billion by 2018, a compound annual growth rate (CAGR) of 6.1%.
This report provides:
- An overview of the global market for cervical cancer diagnostics and therapies.
- Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
- A breakdown of the markets by prophylactics, screening and diagnostics, surgery, radiation therapy, and drug therapy.
- Discussion of cervical cancer biology.
- Delineation of drugs approved to treat the disease, including chemotherapeutic and immunotherapeutic.
- Evaluation of the patent landscape.
- Comprehensive profiles of key companies.
CERVICAL CANCER: GLOBAL MARKET FOR DRUGS AND DIAGNOSTICS, 2012-2018
Source: BCC Research
STUDY GOALS AND OBJECTIVES
This report provides an overview of the current and potential global market for cervical cancer, including treatments and screening and testing technologies. The report provides comprehensive information on cervical cancer, highlighting treatment guidelines. It identifies and analyzes the key trends driving the global cervical cancer therapeutics market. The key objective is to present a comprehensive analysis of current cervical cancer–related technologies and the utilization of various therapeutic, prophylactic, screening, and diagnostic modalities. The report’s focus is on cervical disorders, current treatment strategies and drugs, chemotherapy, and other treatment modalities and testing and screening methods. Important trends in the field, research, new developments, and sales forecasts by treatment and screening categories from 2012 through 2018 are provided in this report. Issues and trends addressed in this report are based on information from industry sources, regulatory and health care policies, demographics, and other factors that directly affect the cervical cancer market.
The report also focuses on the treatment usage patterns in the global cervical cancer therapeutics market, the competitive landscape and emerging players, and pipeline products. It also details opportunities for future players.
REASONS FOR DOING THIS STUDY
This study was conducted to provide detailed information regarding prophylactics, screening, testing, and treatment options for cervical disorders and cancer. There is an increasing need for new and innovative technologies. This industry is experiencing tremendous growth. Many diseases discussed in this report are global issues, and a need exists for newer diagnostic and treatment strategies. This study looks at most types of diagnostic and treatment strategies for the clinical management of cervical disorders and related cancers.
This BCC market research report will increase the awareness of current and emerging drugs and technologies for cervical cancers, including prophylactics, therapeutics, chemotherapy, and surgical therapy.
This report is a detailed study of the global cervical cancer market, with key statistics on and analysis of current drugs and screening and diagnostic technologies, latest trends, market structure, market size, key drug segments, and trends in technology. This study examines the areas of market growth in cervical cancer prevention and treatment strategies from the point of view of manufacturers, product suppliers, health care providers, and consumers of cervical cancer products and services. This study will be of interest largely to the pharmaceutical and biotechnology industries, as well as clinics, hospitals, and research institutes. This report may also prove crucial for investment firms in the concerned sector. This report describes tests and prophylactics currently being used for cervical disorders; cancer diagnosis and prognosis; new developments; spending trends; and revenue prospects for technologies. The report provides market data for 2012 to 2018 and also covers commercial prospects, cervical cancer diagnostic tests, current screening methods in use, and future growth.
SCOPE OF THE STUDY
The scope of this study includes testing, prophylactics vaccines, screening tests and methods, and therapeutics markets for cervical cancers. The report also discusses current technologies, new technologies, cervical cancer incidence, and market projections and market share, along with latest trends and new developments.
Both primary and secondary research methodologies were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers, industry portals and news, government agencies, trade associations, and paid and free databases. The base year of the report is 2012, with forecast data provided through 2018. Historical, base year, and forecast data are provided for each market segment of this report. The report provides a comprehensive review of cervical cancer, including discussion of incidence and development of the disease, drugs currently being used, and diagnostic technologies. The report also reviews technological developments, product innovations/introductions, and recent strategic industry activity of major players across various product categories. Growth rates, global incidence, and projections have been determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in research and development (R&D), and current product growth. Forecasts and projections were based on market trends, potential users, and mergers and acquisitions.
A comprehensive and exhaustive search of the literature was conducted on cervical cancer and disorders; products; global incidence; and drug developments. Secondary sources included scientific journals and articles, textbooks, press releases, marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications. A patent search and analysis were also completed. Some informal interviews were also conducted with experts and personnel in this area at biotech and pharmaceutical companies. Other resources included academic institutions and technology and consulting companies.
Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of products, such as pharmaceutical and biotechnical companies and research institutes. Data were gathered from various industry sources. BCC spoke with officials within the industry and consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases using key terminology were completed. In addition, data were compiled from current financial, trade, and government sources.
ABOUT THE AUTHOR
Usha Nagavarapu is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs involving target identification, including investigational new drug (IND) enabling studies, and assisted out-licensing and portfolio development activities. Her strong focus areas include oncology, dermatology, and cardiovascular diseases. She has extensive experience working with early start-ups to fulfill operational obligations while minimizing overall operational cost and burden.
BCC ONLINE SERVICES
BCC offers an online information retrieval service. Its home page, located at www.bccresearch.com, enables readers to:
- Examine the complete BCC catalog of market research reports and place direct orders.
- Subscribe to any of BCC’s many industry newsletters.
- Read announcements of recently published reports and newly launched newsletters.
- Register for BCC’s well-known conferences.
- Request additional information on any BCC product.
- Take advantage of special offers.
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice, nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or from its use.